Cisplatin versus carboplatin for the treatment of limited-stage small cell lung cancer (LS-SCLC).
Ibrahim Azar(Wayne State University), Hirva Mamdani(Wayne State University), Malini Surapaneni(The Barbara Ann Karmanos Cancer Institute), Daniel Kurtz(Wayne State University), Omid Yazdanpanah(Wayne State University), Seongho Kim(Wayne State University), Adam Austin(University of Florida), Syed Mehdi(Veterans Health Administration), Hyejeong Jang(The Barbara Ann Karmanos Cancer Institute), Amit Chopra(Albany Medical Center Hospital)
Cited by 1
Related Papers
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|116
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
|Frontiers in Cell and Developmental Biology|2020|80
Blood-based tumor biomarkers in lung cancer for detection and treatment
|Translational Lung Cancer Research|2017|75